Lexaria Bioscience announces $4M registered direct offering priced ATM

Lexaria Bioscience (LEXX) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock at a purchase price of $1.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,666,667 shares of common stock. The warrants will have an exercise price of $1.37 per share, will be immediately exercisable and will expire five years from the date of the effectiveness of the resale registration statement registering the shares of common stock issuable upon exercise of the unregistered warrants. The closing of the offering is expected to occur on or about September 29, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The aggregate gross proceeds to the company from the offering are expected to be approximately $4M, before deducting the placement agent fees and other offering expenses payable by the company.